Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Multi-Mode Microplate Readers

By Drug Discovery Trends Editor | December 21, 2009

MDS Analytical Technologies, a leader in innovative solutions for drug discovery and life-sciences research, announced the launch of the Molecular Devices SpectraMax M3 and M4 Multi-Mode Microplate Readers.

These two new systems, which are now commercially available, were designed specifically in response to requests from existing users of SpectraMax Readers for more affordable multi-mode detection capabilities. By offering two new configurations of multi-mode readers that deliver increased capabilities over the M2/M2e Dual-Mode Readers at a more affordable price than the top-of-the-line M5/M5e Multi-Mode Readers, MDS Analytical Technologies can now meet an even greater combination of detection, application, and budgetary needs.

Furthermore, since research needs change continually as science advances, MDS Analytical Technologies designed the M3 and M4 readers as modular systems to ensure users had access to easy upgrade paths. The Molecular Devices SpectraMax M3 Reader provides three detection modes: UV-Vis absorbance, fluorescence intensity, and luminescence, but can be upgraded to include time-resolved fluorescence and/or fluorescence polarization modes. The M4 Reader offers the same modes as the M3 Reader, plus time-resolved fluorescence, and can be upgraded to include fluorescence polarization.

Like all SpectraMax Readers, the new M3 and M4 readers leverage patented technologies to deliver added value to users. The readers are built on a dual-monochromator platform to deliver the convenience of a monochromator-based instrument with sensitivity similar to filter-based platforms. In addition, SpectraMax Readers enable well-volume detection via the patented PathCheck Sensor and superior optical capabilities via a patented Smart Optics Design.

All SpectraMax M Series Readers accommodate a cuvette as well as six-well to 384-well standard microplates. All leverage the same industry-leading SoftMax Pro Data Acquisition and Analysis Software which offers users more than 150 pre-programmed application protocols. In addition, SoftMax Pro GxP Software helps users adhere to United States Food and Drug Administration (FDA) 21CFR Part 11 compliance requirements. Few other microplate readers offer this combination of flexibility, sensitivity, ease-of-use, and brand value while accommodating almost any combination of detection, application, and budgetary needs.

MDS Analytical Technologies


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE